Evidence map›Paper›PMID 40217480›Full record

ReviewJournal of translational medicine2025

Mesenchymal stem cell exosomes therapy for the treatment of traumatic brain injury: mechanism, progress, challenges and prospects.

Ming-Wei Liu, Hua Li, Gui-Fei Xiong, Bin-Ran Zhang, Qiu-Juan Zhang, Shu-Ji Gao, Yan-Lin Zhu, Lin-Ming Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ming-Wei Liu *Department of Emergency, Dali Bai Autonomous Prefecture People's Hospital, Dali, 671000, China. lmw2004210@163.com.ORCID 0000-0002-3728-2350
Hua Li *Department of Emergency, The Third People's Hospital of Yunnan Province, Kunming, China, 650200.
Gui-Fei Xiong *Department of Pain Management, Kaiyuan City People's Hospital of Hani-Yi Autonomous Prefecture of Honghe, KaiYuan, 661600, China.
Bin-Ran ZhangDepartment of Emergency, The First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Qiu-Juan ZhangDepartment of Emergency, The First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Shu-Ji GaoDepartment of Emergency, The First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Yan-Lin ZhuDepartment of Emergency, The First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Lin-Ming ZhangDepartment of Neurology, The First Hospital Affiliated to Kunming Medical University, Kunming, 650032, China. zlmeek@163.com.

Funding

Natural Science Foundation of China 81960350Union Foundation of Yunnan Provincial Science and Technology Department and Kunming Medical University 202201AY070001-091
6 · The paper itself

Abstract

Traumatic brain injury (TBI) is a heterogeneous disease characterized by brain damage and functional impairment caused by external forces. Under the influence of multiple mechanisms, TBI can cause synaptic dysfunction, protein aggregation, mitochondrial dysfunction, oxidative stress, and neuroinflammatory cascade reactions, resulting in a high disability and mortality rate for patients and a heavy burden on families and society. Exosomes are cell-derived vesicles that encapsulate a variety of molecules, including proteins, lipids, mRNAs, and other small biomolecules. Among these, exosomes derived from mesenchymal stem cells (MSCs) have garnered significant attention owing to their therapeutic potential in the nervous system, offering broad clinical applicability. Recent studies have demonstrated that MSC-derived exosome injections in traumatic brain injury models effectively mitigate local inflammatory damage and promote nerve regeneration following injury. Owing to their small size, challenging replication, ease of preservation, and low immunogenicity, MSC exosomes are emerging as a promising therapeutic strategy for traumatic brain injury. This review explores the pathogenesis of traumatic brain injury, the underlying mechanisms of MSC exosome action, and the potential clinical applications of MSC exosomes in the treatment of traumatic brain injury.

Indexed as

Brain Injuries, TraumaticExosomesMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAnimalsHumansMesenchymal stem cell exosomeResearch progressTraumatic brain injury

Identifiers

PMID40217480
PMCPMC11987214

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.